Advantages of CT nano-contrast agent in tumor diagnosis A retrospective study

Abstract

The purpose of this retrospective study was to explore the advantages of computed tomography (CT) nano-contrast agent in tumor diagnosis. A total of 100 patients with malignant tumor who were diagnosed in Shaanxi Province Public Hospital between January 2018 and January 2019 were included in this retrospective study. They were randomly divided into observation and control groups with 50 patients in each group. The patients in the observation group used new type of nano-contrast agent for examination, and the patients in the control group used traditional iohexol contrast agent for examination. The detection rate, misdiagnosis rate, and incidence of adverse reactions were observed. In addition, single photon emission computed tomography or CT scan was performed on patients to observe the radioactive concentration. The detection rate was 100% in the observation group and 84% in the control group, and the difference between the 2 groups was statistically significant (x2=8.763, P=.001). The incidence of adverse reactions was 2% in the observation group and 30% in the control group, and the difference between the 2 groups was significantly different (x2=12.683, P=.000). The radioactive concentration in the observation group was markedly higher than that in the control group (t=19.692, P=.001). The use of CT nano-contrast agent in tumor diagnosis had higher detection rate of tumor and radioactive concentration, and it had lower misdiagnosis rate and adverse reaction rate than traditional iohexol contrast agent. Abbreviations: CT = computed tomography, SPECT = single photon emission computed tomography, T/NT = tumor and nontumor.